Pernicious Anemia
An autoimmune disease causing lack of intrinsic factor, preventing Vitamin B12 absorption, and resulting in severe anemia and progressive nerve damage.
Emergency Management: Severe symptomatic anemia (Hb < 6 g/dL) requiring cautious packed RBC transfusion combined with IV diuretics to prevent heart failure. Severe hypokalemia during initial B12 replacement requiring urgent potassium repletion.
Pernicious anemia is an autoimmune disorder characterized by the destruction of gastric parietal cells, leading to a lack of intrinsic factor (IF). Intrinsic factor is a glycoprotein essential for the absorption of vitamin B12 (cobalamin) in the terminal ileum. The resulting profound vitamin B12 deficiency causes megaloblastic anemia and potentially irreversible neurological damage.
Detailed Overview
It is the most common cause of severe vitamin B12 deficiency globally. The disease is mediated by autoantibodies against parietal cells and intrinsic factor itself. Because the liver stores significant amounts of B12 (enough for 3-5 years), clinical symptoms take years to develop. Once depleted, impaired DNA synthesis affects all rapidly dividing cells, leading to macrocytic erythrocytes and hypersegmented neutrophils. Neurologically, B12 deficiency impairs the methylation of myelin, leading to subacute combined degeneration of the spinal cord (demyelination of dorsal and lateral columns).
Epidemiology & Demographics
Prevalence is approximately 0.1% in the general population, but rises to 1.9% in individuals over age 60. Highest prevalence in individuals of Northern European and African descent. Women are affected slightly more than men.
Etiological Mechanism
It is a chronic, CD4 T-cell mediated autoimmune disease targeting the H+/K+-ATPase proton pump of gastric parietal cells. It is frequently associated with other autoimmune endocrinopathies (Type 1 diabetes, autoimmune thyroid disease, vitiligo, Addison's disease).
Primary Causes
The primary cause is the autoimmune destruction of the gastric body and fundus mucosa (autoimmune metaplastic atrophic gastritis, AMAG), leading to achlorhydria and absent intrinsic factor.
Autoimmune destruction leads to autoimmune atrophic gastritis. The loss of parietal cells results in achlorhydria (low stomach acid), which impairs the release of B12 from food proteins. Crucially, the lack of intrinsic factor prevents B12 from being transported across the enterocytes in the terminal ileum. B12 is a crucial cofactor for two enzymes: methionine synthase (needed for DNA synthesis, lack thereof causes megaloblastic anemia) and methylmalonyl-CoA mutase (needed for myelin synthesis, lack thereof causes neurological deficits).
Diagnostic Criteria & Guidelines
Diagnosis requires demonstrating B12 deficiency (low serum B12 with elevated methylmalonic acid and homocysteine) in the setting of megaloblastic anemia, accompanied by autoimmune markers (positive Anti-Intrinsic Factor antibodies or Anti-Parietal Cell antibodies).
Intramuscular Cyanocobalamin or Hydroxocobalamin injections. Typical induction regimen: 1,000 mcg IM daily for 1 week, then 1,000 mcg weekly for 1 month, followed by maintenance of 1,000 mcg IM monthly for life. Note: Must monitor for severe hypokalemia during the first few days of therapy as rapid red blood cell production consumes potassium.
Second-Line & Adjunctive Therapy
High-dose oral Cyanocobalamin (1,000 to 2,000 mcg daily). Despite the lack of intrinsic factor, about 1% of a massive oral dose is absorbed via passive diffusion, which is sufficient for maintenance in compliant patients. However, IM injections are preferred for initial therapy and in patients with neurological symptoms.
Surgical & Procedural Management
None for the anemia itself. Endoscopic mucosal resection or gastrectomy may be required if gastric cancer or large carcinoid tumors develop.
Patient Counseling & Advice
Inform the patient that this is a lifelong condition requiring permanent B12 replacement. Reassure them that with treatment, the anemia will completely resolve within weeks. Warn them that neurological symptoms may take months to improve and, if long-standing before treatment, may be permanent. Discuss the need for periodic monitoring for gastric cancer.
Follow-Up & Monitoring Schedule
Check CBC and reticulocyte count 7-10 days after starting therapy (reticulocyte crisis indicates successful treatment). Potassium should be monitored during the first week. EGD is recommended at diagnosis to evaluate for gastric neoplasms, with follow-up intervals determined by gastroenterology based on findings.
Preventive Strategies
Cannot be prevented due to autoimmune nature. Secondary prevention (preventing severe complications) is achieved through early recognition and lifelong B12 therapy.
Excellent with lifelong treatment; normal life expectancy. Hematologic abnormalities reverse rapidly. Neurologic recovery is inversely proportional to the duration of symptoms prior to treatment.